136 related articles for article (PubMed ID: 27447046)
1. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
Maolanon AR; Madsen AS; Olsen CA
Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
[TBL] [Abstract][Full Text] [Related]
2. Computational exploration of zinc binding groups for HDAC inhibition.
Chen K; Xu L; Wiest O
J Org Chem; 2013 May; 78(10):5051-5. PubMed ID: 23586590
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
4. Chemo-proteomics exploration of HDAC degradability by small molecule degraders.
Xiong Y; Donovan KA; Eleuteri NA; Kirmani N; Yue H; Razov A; Krupnick NM; Nowak RP; Fischer ES
Cell Chem Biol; 2021 Oct; 28(10):1514-1527.e4. PubMed ID: 34314730
[TBL] [Abstract][Full Text] [Related]
5. The nonepigenetic role for small molecule histone deacetylase inhibitors in the regulation of cardiac function.
Romanick SS; Ferguson BS
Future Med Chem; 2019 Jun; 11(11):1345-1356. PubMed ID: 31161804
[TBL] [Abstract][Full Text] [Related]
6. Lysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulation.
Van Dyke MW
ChemMedChem; 2014 Mar; 9(3):511-22. PubMed ID: 24449617
[TBL] [Abstract][Full Text] [Related]
7. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor.
Han H; Feng X; He T; Wu Y; He T; Yue Z; Zhou W
Chem Biol Drug Des; 2024 Jan; 103(1):e14366. PubMed ID: 37776270
[TBL] [Abstract][Full Text] [Related]
8. Selective class IIa HDAC inhibitors: myth or reality.
Di Giorgio E; Gagliostro E; Brancolini C
Cell Mol Life Sci; 2015 Jan; 72(1):73-86. PubMed ID: 25189628
[TBL] [Abstract][Full Text] [Related]
9. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
Ru J; Wang Y; Li Z; Wang J; Ren C; Zhang J
Eur J Med Chem; 2023 Dec; 261():115800. PubMed ID: 37708798
[TBL] [Abstract][Full Text] [Related]
10. Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel.
Wu R; Lu Z; Cao Z; Zhang Y
J Am Chem Soc; 2011 Apr; 133(16):6110-3. PubMed ID: 21456530
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain.
Seo YJ; Muench L; Reid A; Chen J; Kang Y; Hooker JM; Volkow ND; Fowler JS; Kim SW
Bioorg Med Chem Lett; 2013 Dec; 23(24):6700-5. PubMed ID: 24210501
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies.
Sandonà M; Cavioli G; Renzini A; Cedola A; Gigli G; Coletti D; McKinsey TA; Moresi V; Saccone V
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901738
[TBL] [Abstract][Full Text] [Related]
13. Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.
Wang D
Curr Top Med Chem; 2009; 9(3):241-56. PubMed ID: 19355989
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of histone deacetylases in ocular diseases.
Jun JH; Kim JS; Palomera LF; Jo DG
Arch Pharm Res; 2024 Jan; 47(1):20-39. PubMed ID: 38151648
[TBL] [Abstract][Full Text] [Related]
15. HDAC-targeting epigenetic modulators for cancer immunotherapy.
Cheng B; Pan W; Xiao Y; Ding Z; Zhou Y; Fei X; Liu J; Su Z; Peng X; Chen J
Eur J Med Chem; 2024 Feb; 265():116129. PubMed ID: 38211468
[TBL] [Abstract][Full Text] [Related]
16. Hydrazides as Potential HDAC Inhibitors: Structure-activity Relationships and Biological Implications.
Banerjee S; Baidya SK; Adhikari N; Jha T; Ghosh B
Curr Top Med Chem; 2023; 23(25):2343-2372. PubMed ID: 37038677
[TBL] [Abstract][Full Text] [Related]
17. A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors.
Drakontaeidi A; Pontiki E
Pharmaceuticals (Basel); 2023 Nov; 16(12):. PubMed ID: 38139766
[TBL] [Abstract][Full Text] [Related]
18. Heterocycles-Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years.
Raucci A; Castiello C; Mai A; Zwergel C; Valente S
ChemMedChem; 2024 May; ():e202400194. PubMed ID: 38726979
[TBL] [Abstract][Full Text] [Related]
19. Synergistic therapeutics: Co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment.
Shetty MG; Pai P; Padavu M; Satyamoorthy K; Kampa Sundara B
Eur J Med Chem; 2024 Apr; 269():116324. PubMed ID: 38520762
[TBL] [Abstract][Full Text] [Related]
20. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Imai Y; Maru Y; Tanaka J
Cancer Sci; 2016 Nov; 107(11):1543-1549. PubMed ID: 27554046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
